APA (7th ed.) Citation

Zervanos, D., Galatou, E., Miliotou, A. N., Theodoroula, N. F., Grigoriadis, N., & Vizirianakis, I. S. (2025). Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting. Future Pharmacology, 5(3), 43. https://doi.org/10.3390/futurepharmacol5030043

Chicago Style (17th ed.) Citation

Zervanos, Damianos-Ioannis, Eleftheria Galatou, Androulla N. Miliotou, Nikoleta F. Theodoroula, Nikolaos Grigoriadis, and Ioannis S. Vizirianakis. "Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting." Future Pharmacology 5, no. 3 (2025): 43. https://doi.org/10.3390/futurepharmacol5030043.

MLA (9th ed.) Citation

Zervanos, Damianos-Ioannis, et al. "Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting." Future Pharmacology, vol. 5, no. 3, 2025, p. 43, https://doi.org/10.3390/futurepharmacol5030043.